MCID: VGT001
MIFTS: 50

Vogt-Koyanagi-Harada Disease malady

Categories: Rare diseases, Neuronal diseases, Eye diseases, Immune diseases

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 65UMLS, 27ICD10, 29ICD9CM, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet
See all MalaCards sources

Aliases & Descriptions for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 10 45 47 12 51
Uveomeningoencephalitic Syndrome 10 36 65
Uveomenigitic Syndrome 45 51
Vogt-Koyanagi-Harada Syndrome 45
 
Vogt-Koyanagi Syndrome 10
Harada's Disease 10
Vkh Syndrome 45
Vkh Disease 45

Characteristics:

Orphanet epidemiological data:

51
vogt-koyanagi-harada disease:
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy

Classifications:



External Ids:

Disease Ontology10 DOID:12297
ICD9CM29 363.22, 364.24
MeSH36 D014607
NCIt42 C85218
Orphanet51 3437
ICD10 via Orphanet28 H20.8, H30.8
UMLS65 C0042170

Summaries for Vogt-Koyanagi-Harada Disease

About this section
NIH Rare Diseases:45 Vogt-koyanagi-harada disease (vkh disease) is a condition that involves chronic inflammation of melanocytes, which are specialized cells that produce a pigment called melanin. melanin is the substance that gives skin, hair, and eyes their color. melanin is also found in the retina, where it plays a role in normal vision. people with vkh disease usually develop vision and hearing disturbances first, followed by signs of skin problems. the most common symptoms include headaches, panuveitis, vitiligo, hair loss (alopecia), and inner ear disturbances. neurological symptoms may also occur. the exact cause of vkh disease is not well understood, but research suggests it is an autoimmune disease. it is more common in people with darker skin pigmentation including asian, middle eastern, hispanic, and native american populations. last updated: 1/8/2015

MalaCards based summary: Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to retinitis and heavy chain deposition disease, and has symptoms including sensorineural hearing impairment, abnormality of the eyelashes and visual impairment. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase, Non-Receptor Type 22), and among its related pathways are TCR signaling in naive CD4+ T cells and Antigen Presentation- Folding, assembly and peptide loading of class I MHC. Affiliated tissues include skin, eye and retina, and related mouse phenotype renal/urinary system.

Disease Ontology:10 A hypersensitivity reaction type II disease that is caused by T helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

Related Diseases for Vogt-Koyanagi-Harada Disease

About this section

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to vogt-koyanagi-harada disease

Symptoms for Vogt-Koyanagi-Harada Disease

About this section

Symptoms:

 51 (show all 13)
  • mild visual loss/impaired visual acuity
  • absent/decreased/thin eyebrows
  • absent/decreased lashes
  • sensorineural deafness/hearing loss
  • irregular/patchy skin hypopigmentation
  • hypotrichosis/atrichia/atrichiasis/scalp hairlessness
  • premature greying of hair
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • glaucoma
  • cataract/lens opacification
  • retinal detachment
  • visual loss/blindness/amblyopia
  • short stature/dwarfism/nanism

HPO human phenotypes related to Vogt-Koyanagi-Harada Disease:

(show all 13)
id Description Frequency HPO Source Accession
1 sensorineural hearing impairment hallmark (90%) HP:0000407
2 abnormality of the eyelashes hallmark (90%) HP:0000499
3 visual impairment hallmark (90%) HP:0000505
4 hypopigmented skin patches hallmark (90%) HP:0001053
5 premature graying of hair hallmark (90%) HP:0002216
6 abnormal hair quantity hallmark (90%) HP:0011362
7 cognitive impairment hallmark (90%) HP:0100543
8 aplasia/hypoplasia of the eyebrow hallmark (90%) HP:0100840
9 glaucoma typical (50%) HP:0000501
10 visual impairment typical (50%) HP:0000505
11 cataract typical (50%) HP:0000518
12 retinal detachment typical (50%) HP:0000541
13 short stature typical (50%) HP:0004322

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

About this section

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 14)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bevacizumabapproved, investigationalPhase 31875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
2Angiogenesis Modulating AgentsPhase 33611
3Angiogenesis InhibitorsPhase 33688
4
Azathioprineapproved153446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
 
HMS1920E17
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
5
Mycophenolate mofetilapproved, investigational898128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate Mofetil
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
6
Mycophenolic acidapproved89824280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
Melbex
 
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolic Acid
Mycophenolsaeure
Myfortic
7Povidone129
8Povidone-Iodine134
9
Iodine4947553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
10cadexomer iodine456
11Anti-Bacterial Agents9140
12Antibiotics, Antitubercular5971
13Cyclosporins873
14Immunosuppressive Agents10422

Interventional clinical trials:

idNameStatusNCT IDPhase
1Intravitreal Bevacizumab for Inflammatory Neovascular MembranesCompletedNCT00407121Phase 3
2Safety and Efficacy of AIN457 in Noninfectious UveitisCompletedNCT00685399Phase 2
3Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective StudyActive, not recruitingNCT02015351

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease


Cochrane evidence based reviews: uveomeningoencephalitic syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

About this section

Anatomical Context for Vogt-Koyanagi-Harada Disease

About this section

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

33
Skin, Eye, Retina, Lung, Breast, Heart, Kidney

Animal Models for Vogt-Koyanagi-Harada Disease or affiliated genes

About this section

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053678.9FAS, HLA-DQB1, IFNG, IL17A, PTPN22, TYR

Publications for Vogt-Koyanagi-Harada Disease

About this section

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50)    (show all 315)
idTitleAuthorsYear
1
Contribution of the Juxtatransmembrane Intracellular Regions to the Time Course and Permeation of ATP-gated P2X7 Receptor Ion Channels. (25903136)
2015
2
Growth Assessment and the Risk of Growth Retardation in Congenital Diaphragmatic Hernia: A Long-Term Follow-Up Study from the Japanese Congenital Diaphragmatic Hernia Study Group. (26509310)
2015
3
Low pregnancy-associated plasma protein A level in the first trimester. (25316741)
2014
4
Er:YAG laser irradiation to control the progression of enamel erosion: an in situ study. (24985348)
2014
5
Abdominoplasty and thoraco-epigastric flaps for large anterior trunk defects after dermatofibrosarcoma protuberans wide resection: Two illustrative cases. (23219975)
2013
6
Levels of potential oral cancer salivary mRNA biomarkers in oral cancer patients in remission and oral lichen planus patients. (23892499)
2013
7
Seroprevalences of varicella-zoster virus, herpes simplex virus and cytomegalovirus in a cross-sectional study in Mexico. (24021305)
2013
8
Epididymo-orchitis: an unusual manifestation of salmonellosis. (22138654)
2012
9
Cardiogenic shock induced by basal septal hypertrophy and left ventricular outflow tract dynamic obstruction in a critically ill patient with sepsis. (22390968)
2012
10
A child with bone fractures and dysmorphic features: remember of pycnodysostosis and craniosynostosis. (23175007)
2012
11
DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. (21115975)
2011
12
Needle-free jet injection of DNA and protein vaccine of the far-eastern subtype of tick-borne encephalitis virus induces protective immunity in mice. (22004565)
2011
13
Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. (19878098)
2010
14
Ras homolog enriched in brain (Rheb) enhances apoptotic signaling. (20685651)
2010
15
Nanoparticle interaction with model lung surfactant monolayers. (19846443)
2010
16
Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases. (19929789)
2009
17
Hermansky-Pudlak syndrome type 1 in patients of Indian descent. (19398212)
2009
18
Epidural abscess treated with a medial supraorbital craniotomy through an incision in the eyebrow. Case report. (18352786)
2008
19
Eyeball luxation in Bacillus cereus-induced panophthalmitis following a double-penetrating ocular injury. (18991051)
2008
20
ER-bound PTP1B is targeted to newly forming cell-matrix adhesions. (16522684)
2006
21
Erythrokeratoderma variabilis successfully treated with topical tazarotene. (16918639)
2006
22
The relationship of VEGF and PGE2 expression to extracellular matrix remodelling of the tenosynovium in the carpal tunnel syndrome. (15538733)
2004
23
Ataxin-2 promotes apoptosis of human neuroblastoma cells. (12545161)
2003
24
Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomes. (12359427)
2002
25
Up-regulated expression of a novel gene in activated human peripheral blood mononuclear cells that is a truncated paralog of the human system L-amino acid transporter 1. (12009310)
2002
26
Autoantibodies to photoreceptor membrane proteins and outer plexiform layer in patients with cancer-associated retinopathy. (12067305)
2002
27
Selective photocoagulation in Coats' disease: ten-year follow-up. (12510719)
2002
28
The effect of feeding on cerebrospinal fluid corticotropin-releasing hormone levels in humans. (11406119)
2001
29
PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. (10679924)
2000
30
Regulated cleavage of a contact-mediated axon repellent. (10958785)
2000
31
Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis. (11086654)
2000
32
Clinical significance of serum neuron-specific enolase in non-small cell lung cancer]. (9617138)
1998
33
Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease. (9698685)
1998
34
Multiple epitope labeling by the exclusive use of alkaline phosphatase conjugates in immunohistochemistry. (9792421)
1998
35
Arginine-164-tryptophan substitution in connexin32 associated with X linked dominant Charcot-Marie-Tooth disease. (8733054)
1996
36
p53 mutations in non-small cell lung carcinomas in Hong Kong. (8617082)
1996
37
Deregulated expression of PAX5 in medulloblastoma. (7777574)
1995
38
Somatostatin, galanin and peptide histidine isoleucine in the newborn and adult human trigeminal ganglion and spinal nucleus: immunohistochemistry, neuronal morphometry and colocalization with substance P. (7531454)
1994
39
Does intravenous albumin prevent ovarian hyperstimulation syndrome? (8046036)
1994
40
Sonographic lung surface evaluation in pulmonary sarcoidosis: preliminary results. (8015046)
1994
41
Changes in cell population and tumor necrosis factor, interleukin-6, and interleukin-8 in malignant pleural effusions after treatment with intrapleural tetracycline. (8503562)
1993
42
Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation. (8098142)
1993
43
Primary biphasic synovial sarcoma of the orbit. (1313455)
1992
44
Otosclerosis. Correlation of clinical incidence and abnormal TIMP gene expression. (1659291)
1991
45
Diagnosis of familial amyloid polyneuropathy--gene analysis with primer-directed enzymatic amplification of DNA, isolation of plasma variant prealbumin and immunohistochemical identification of tissue amyloid protein]. (1655325)
1991
46
The Dandy-Walker syndrome. Relevance to anaesthesia and intensive care. (2205120)
1990
47
Viremia and neutralizing antibody response in infants with exanthem subitum. (2647944)
1989
48
Corticosteroid binding globulin, testosterone-estradiol binding globulin, and androgen binding protein belong to protein families distinct from steroid receptors. (3386241)
1988
49
An electroencephalographic study of glossopharyngeal neuralgia with syncope. (3355404)
1988
50
The epidemiology of meningococcal meningitis in the Netherlands in recent years, with special reference to the epidemic of 1966. (4982615)
1969

Variations for Vogt-Koyanagi-Harada Disease

About this section

Expression for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section
Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show top 26)    (show all 27)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.7CD8A, HLA-A, HLA-DRB1
29.5HLA-A, HLA-B, HLA-C
3
Show member pathways
9.4CD8A, HLA-A, IFNG
49.4CD8A, HLA-DQB1, HLA-DRB1, PTPN22
59.3CD8A, IFNG, IL17A
69.3HLA-B, IFNA2, IFNG
79.2CD8A, IFNA2, IFNG
89.2CD8A, IFNA2, IFNG
9
Show member pathways
9.2CD8A, IFNA2, IFNG
10
Show member pathways
9.1CD8A, HLA-A, HLA-DRB1, IFNG
11
Show member pathways
9.1IFNG, IL17A, TGFBR3
12
Show member pathways
9.1IFNG, IL17A, TGFBR3
139.1HLA-DQB1, HLA-DRB1, IFNG, IL17A
149.0HLA-DQB1, HLA-DRB1, IFNA2, IFNG
15
Show member pathways
8.9HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
168.9HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
178.9HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
188.6CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
198.4HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNG
208.3CD8A, HLA-A, HLA-B, HLA-C, KIR2DL2
21
Show member pathways
8.2HLA-A, HLA-B, HLA-C, IFNA2, IFNG, IL17A
22
Show member pathways
8.0HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNA2
23
Show member pathways
7.7FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
24
Show member pathways
6.8FAS, HLA-A, HLA-B, HLA-C, IFNA2, IFNG
25
Show member pathways
6.5CD8A, HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1
26
Show member pathways
5.6CD8A, FAS, HLA-A, HLA-B, HLA-C, HLA-DQB1

GO Terms for genes affiliated with Vogt-Koyanagi-Harada Disease

About this section

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1integral component of lumenal side of endoplasmic reticulum membraneGO:007155610.1HLA-C, HLA-DQB1
2cell surfaceGO:00099869.5HLA-A, HLA-B, HLA-C
3ER to Golgi transport vesicle membraneGO:00125079.2HLA-A, HLA-C, HLA-DQB1, HLA-DRB1

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1immunoglobulin production involved in immunoglobulin mediated immune responseGO:000238110.5HLA-DQB1, HLA-DRB1
2protection from natural killer cell mediated cytotoxicityGO:004227010.5HLA-A, HLA-B
3positive regulation of T cell mediated cytotoxicityGO:000191610.5HLA-A, HLA-B
4inflammatory cell apoptotic processGO:000692510.3FAS, IFNG
5positive regulation of interleukin-23 productionGO:003274710.3IFNG, IL17A
6positive regulation of peptidyl-serine phosphorylation of STAT proteinGO:003314110.1IFNA2, IFNG
7positive regulation of osteoclast differentiationGO:00456729.9IFNG, IL17A
8antigen processing and presentation of peptide antigen via MHC class IGO:00024749.8HLA-A, HLA-B, HLA-C
9interferon-gamma-mediated signaling pathwayGO:00603339.2HLA-A, HLA-B, HLA-C, IFNG
10cell surface receptor signaling pathwayGO:00071669.0CD8A, FAS, IFNA2, IFNG
11antigen processing and presentationGO:00198828.8HLA-A, HLA-B, HLA-C, HLA-DQB1, HLA-DRB1, IFNG
12immune responseGO:00069558.6FAS, HLA-DRB1, IFNG, IL17A, TGFBR3

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptide antigen bindingGO:00426059.9HLA-A, HLA-B

Sources for Vogt-Koyanagi-Harada Disease

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet